Insulet faces Aug. 31 lead plaintiff deadline after $90 stock slide

Insulet faces an Aug. 31 deadline for investors to seek lead plaintiff in a securities class action after two Omnipod recalls erased $90 a share.

"The complaint alleges Insulet's manufacturing controls were defective, creating a foreseeable risk that Omnipod products would require corrections," Joseph E. Levi, founding partner at Levi & Korsinsky, said.

The lawsuit, filed in the US District Court for the District of Massachusetts, covers investors who bought Insulet securities between Feb. 21, 2025 and May 26, 2026. On March 12, 2026, Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue. The stock fell $16.23, or 6.88 percent, to close at $219.84 on March 13. On May 26, Insulet disclosed a second correction covering about 7 million Pods across the Omnipod 5, Omnipod Dash and Omnipod Eros lines — 8.5 percent of 2025 global production — citing a cannula tear that could cause insulin under-delivery. Shares dropped another $7.79, or 5.07 percent, to $146.01 on May 27.

The two disclosures cut Insulet's stock from about $236 to $146.01, a cumulative decline of roughly $90 a share. The complaint names six current and former executives as individual defendants, including Chief Executive Officer Ashley McEvoy, former CEO James Hollingshead, Chief Financial Officer Flavia Pease and Chief Medical Officer Trang Ly.

The lead plaintiff deadline applies only to investors seeking to direct the litigation; class members who do not apply can still share in any recovery. Under the Private Securities Litigation Reform Act, the court typically appoints the movant with the largest financial interest who is adequate and typical of the class.

Analysts have responded to the quality concerns. BTIG cut its price target on Insulet to $235 from $260, citing continued negative investor sentiment and the risk of reputation damage. Goldman Sachs said it did not fully subscribe to the company's reiterated guidance.

The case, Hu v. Insulet Corporation, No. 26-cv-013062, charges the company and executives with violating the Securities Exchange Act of 1934. Faruqi & Faruqi and Robbins Geller Rudman & Dowd are also investigating claims on behalf of shareholders.

The deadline sets up a key test of investor appetite to pursue claims against a medical-device maker whose flagship product faces quality questions. Insulet's next catalyst is the lead plaintiff appointment, expected in the weeks after the Aug. 31 deadline, which will determine how the litigation proceeds.

This article is for informational purposes only and does not constitute investment advice.